Sartorius Stedim Biotech (FR:DIM) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Sartorius Stedim Biotech has released its first-half 2024 financial results and provides forecasts for the rest of the year. The internationally active biopharmaceutical partner reported a turnover of approximately 2.8 billion euros in 2023 and employs around 10,600 people globally. The full investor news is available on the company’s website.
For further insights into FR:DIM stock, check out TipRanks’ Stock Analysis page.
